http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 28 Jul 2026 08:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26823125.html si-local-file:///var/storage/secattach/20260728/26823125.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26823125.html Tue, 28 Jul 2026 08:36:00 -0400 LAB O.00073707 http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26823125.html si-local-file:///var/storage/secattach/20260728/26823125.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26823125.html Tue, 28 Jul 2026 08:36:00 -0400 LAB O.00073707 http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26822974.html si-local-file:///var/storage/secattach/20260728/26822974.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26822974.html Tue, 28 Jul 2026 08:23:00 -0400 LAB O.00073707 http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26822974.html si-local-file:///var/storage/secattach/20260728/26822974.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++STANDARD+BIOTOOLS+INC.+++++++++++++++++Filed+by%3A+STANDARD+BIOTOOLS+INC./26822974.html Tue, 28 Jul 2026 08:23:00 -0400 LAB O.00073707 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++STANDARD+BIOTOOLS+INC.++++For%3A+Jul+24/26822965.html si-local-file:///var/storage/secattach/20260728/26822965.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++STANDARD+BIOTOOLS+INC.++++For%3A+Jul+24/26822965.html Tue, 28 Jul 2026 08:20:00 -0400 LAB O.00073707 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++STANDARD+BIOTOOLS+INC.++++For%3A+Jul+24/26822965.html si-local-file:///var/storage/secattach/20260728/26822965.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++STANDARD+BIOTOOLS+INC.++++For%3A+Jul+24/26822965.html Tue, 28 Jul 2026 08:20:00 -0400 LAB O.00073707 http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html <p>Standard BioTools Inc. (NASDAQ: LAB) announced it has agreed to sell its Mass Cytometry business to Multiplex Bio, a newly formed entity led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, as the company advances its pending merger with Treeline Biosciences, Inc.</p> <p>The transaction is valued at up to $10 million, comprising a seller's note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing. The deal is expected to close by the end of 2026, subject http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html Tue, 28 Jul 2026 08:01:21 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html <p>Standard BioTools Inc. (NASDAQ: LAB) announced it has agreed to sell its Mass Cytometry business to Multiplex Bio, a newly formed entity led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, as the company advances its pending merger with Treeline Biosciences, Inc.</p> <p>The transaction is valued at up to $10 million, comprising a seller's note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing. The deal is expected to close by the end of 2026, subject http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html Tue, 28 Jul 2026 08:01:21 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html <p>Standard BioTools Inc. (NASDAQ: LAB) announced it has agreed to sell its Mass Cytometry business to Multiplex Bio, a newly formed entity led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, as the company advances its pending merger with Treeline Biosciences, Inc.</p> <p>The transaction is valued at up to $10 million, comprising a seller's note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing. The deal is expected to close by the end of 2026, subject http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html Tue, 28 Jul 2026 08:01:21 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html <p>Standard BioTools Inc. (NASDAQ: LAB) announced it has agreed to sell its Mass Cytometry business to Multiplex Bio, a newly formed entity led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, as the company advances its pending merger with Treeline Biosciences, Inc.</p> <p>The transaction is valued at up to $10 million, comprising a seller's note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing. The deal is expected to close by the end of 2026, subject http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html Tue, 28 Jul 2026 08:01:21 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html <p>Standard BioTools Inc. (NASDAQ: LAB) announced it has agreed to sell its Mass Cytometry business to Multiplex Bio, a newly formed entity led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, as the company advances its pending merger with Treeline Biosciences, Inc.</p> <p>The transaction is valued at up to $10 million, comprising a seller's note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing. The deal is expected to close by the end of 2026, subject http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html Tue, 28 Jul 2026 08:01:21 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html <p>Standard BioTools Inc. (NASDAQ: LAB) announced it has agreed to sell its Mass Cytometry business to Multiplex Bio, a newly formed entity led by Michael Johnson, PhD, Tom Villani, PhD, and Charles Coffman, as the company advances its pending merger with Treeline Biosciences, Inc.</p> <p>The transaction is valued at up to $10 million, comprising a seller's note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools also agreed to provide Multiplex Bio with a working capital loan of up to $10 million at closing. The deal is expected to close by the end of 2026, subject http://www.streetinsider.com/Mergers+and+Acquisitions/Standard+BioTools+sells+mass+cytometry+unit%2C+gets+%2430M+from+Illumina/26822769.html Tue, 28 Jul 2026 08:01:21 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Press+Releases/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html <p align="center"><em>Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms</em></p> <p align="center"><em>Receives Approximately $30 Million in Negotiated Buyout Related to Contingent Consideration Obligations From Illumina’s Acquisition of SomaLogic Business</em></p> <p align="left">BOSTON, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (&quot;Standard BioTools&quot; or the &quot;Company&quot;) today announced the following updates in connection with the Company’s previously announced merger with Treeline Biosciences, Inc. (“Treeline”):</p> <ul type="disc"><li>Agreement to sell its Mass Cytometry business to http://www.streetinsider.com/Globe+Newswire/Standard+BioTools+Announces+Sale+of+Mass+Cytometry+Business+and+Illumina%E2%80%99s+Buyout+of+Contingent+Payments+to+Advance+Merger+with+Treeline+Biosciences/26822760.html Tue, 28 Jul 2026 08:00:00 -0400 A.23735662 A.50216938 LAB O.00073707 O.03285413 O.61332621 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++STANDARD+BIOTOOLS+INC.++++For%3A+Jul+23++Filed+by%3A+Kim+Hanjoon+Alex/26820776.html si-local-file:///var/storage/secattach/20260727/26820776.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++STANDARD+BIOTOOLS+INC.++++For%3A+Jul+23++Filed+by%3A+Kim+Hanjoon+Alex/26820776.html Mon, 27 Jul 2026 19:29:00 -0400 LAB O.00073707